These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12070356)

  • 1. Models and modeling systems in Alzheimer disease drug discovery.
    Khachaturian ZS
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S9-S12. PubMed ID: 12070356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers to Alzheimer disease drug discovery and development in academia.
    Van Eldik LJ; Koppal T; Watterson DM
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S18-28. PubMed ID: 12070358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to drug discovery and development for Alzheimer disease.
    Fillit HM; O'Connell AW; Brown WM; Altstiel LD; Anand R; Collins K; Ferris SH; Khachaturian ZS; Kinoshita J; Van Eldik L; Dewey CF
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S1-8. PubMed ID: 12070355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systems biology in drug discovery.
    Butcher EC; Berg EL; Kunkel EJ
    Nat Biotechnol; 2004 Oct; 22(10):1253-9. PubMed ID: 15470465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to Alzheimer disease drug discovery and development in the biotechnology industry.
    Altstiel LD
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S29-32. PubMed ID: 12070359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers to Alzheimer disease drug discovery and drug development in the pharmaceutical industry.
    Anand R
    Alzheimer Dis Assoc Disord; 2002; 16 Suppl 1():S33-9. PubMed ID: 12070360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.
    Hausheer FH; Kochat H; Parker AR; Ding D; Yao S; Hamilton SE; Petluru PN; Leverett BD; Bain SH; Saxe JD
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S3-15. PubMed ID: 12819940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the 3D structure of GPCRs: advances and application to drug discovery.
    Becker OM; Shacham S; Marantz Y; Noiman S
    Curr Opin Drug Discov Devel; 2003 May; 6(3):353-61. PubMed ID: 12833668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents.
    Lahiri DK; Rogers JT; Greig NH; Sambamurti K
    Curr Pharm Des; 2004; 10(25):3111-9. PubMed ID: 15544501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease.
    Ambure P; Roy K
    Curr Drug Targets; 2017; 18(5):522-533. PubMed ID: 26343117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer's Disease: An Update.
    de Freitas Silva M; Dias KST; Gontijo VS; Ortiz CJC; Viegas C
    Curr Med Chem; 2018; 25(29):3491-3525. PubMed ID: 29332563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunities and challenges in antiparasitic drug discovery.
    Pink R; Hudson A; Mouriès MA; Bendig M
    Nat Rev Drug Discov; 2005 Sep; 4(9):727-40. PubMed ID: 16138106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial biogenesis: pharmacological approaches.
    Valero T
    Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico.
    Shaikh SA; Jain T; Sandhu G; Latha N; Jayaram B
    Curr Pharm Des; 2007; 13(34):3454-70. PubMed ID: 18220783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring hot flashes: summary of a National Institutes of Health workshop.
    Miller HG; Li RM
    Mayo Clin Proc; 2004 Jun; 79(6):777-81. PubMed ID: 15182093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational systems biology and dose-response modeling in relation to new directions in toxicity testing.
    Zhang Q; Bhattacharya S; Andersen ME; Conolly RB
    J Toxicol Environ Health B Crit Rev; 2010 Feb; 13(2-4):253-76. PubMed ID: 20574901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scientific workflows as productivity tools for drug discovery.
    Shon J; Ohkawa H; Hammer J
    Curr Opin Drug Discov Devel; 2008 May; 11(3):381-8. PubMed ID: 18428092
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.